JP2000515517A - 成長ホルモン放出特性を有する化合物 - Google Patents
成長ホルモン放出特性を有する化合物Info
- Publication number
- JP2000515517A JP2000515517A JP10506465A JP50646598A JP2000515517A JP 2000515517 A JP2000515517 A JP 2000515517A JP 10506465 A JP10506465 A JP 10506465A JP 50646598 A JP50646598 A JP 50646598A JP 2000515517 A JP2000515517 A JP 2000515517A
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- methyl
- ethyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 259
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 41
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 41
- 239000000122 growth hormone Substances 0.000 title claims abstract description 41
- 230000003578 releasing effect Effects 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 28
- 206010062767 Hypophysitis Diseases 0.000 claims abstract description 12
- 230000012010 growth Effects 0.000 claims abstract description 12
- 210000003635 pituitary gland Anatomy 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 230000004936 stimulating effect Effects 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- 235000020244 animal milk Nutrition 0.000 claims abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 360
- 239000001257 hydrogen Substances 0.000 claims description 360
- -1 C1-6Alkoxy Chemical group 0.000 claims description 279
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 263
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 138
- 239000000203 mixture Substances 0.000 claims description 100
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 98
- 150000002431 hydrogen Chemical class 0.000 claims description 77
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 150000002367 halogens Chemical class 0.000 claims description 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 19
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- BKMADDIPSQRZPU-ONEGZZNKSA-N (e)-5-amino-5-methylhex-2-enoic acid Chemical compound CC(C)(N)C\C=C\C(O)=O BKMADDIPSQRZPU-ONEGZZNKSA-N 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- 230000000638 stimulation Effects 0.000 claims description 9
- 206010053759 Growth retardation Diseases 0.000 claims description 8
- 231100000001 growth retardation Toxicity 0.000 claims description 8
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 229940080818 propionamide Drugs 0.000 claims description 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- BZEUYEFVVDTLOD-UHFFFAOYSA-N hex-2-enamide Chemical compound CCCC=CC(N)=O BZEUYEFVVDTLOD-UHFFFAOYSA-N 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 239000008196 pharmacological composition Substances 0.000 claims description 5
- IEEUKABHJLYTDI-UDKPXMKSSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl(2-phenylethyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)N(C)CCC1=CC=CC=C1 IEEUKABHJLYTDI-UDKPXMKSSA-N 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000013632 homeostatic process Effects 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- YZRHJTFBPBFLSM-ALGFLVEBSA-N (2r)-2-[(5r)-4-[(e)-5-amino-5-methylhex-2-enoyl]-5-(naphthalen-2-ylmethyl)-2-oxopiperazin-1-yl]-n-methyl-3-phenylpropanamide Chemical compound C([C@H](C(=O)NC)N1C(CN([C@H](CC=2C=C3C=CC=CC3=CC=2)C1)C(=O)\C=C\CC(C)(C)N)=O)C1=CC=CC=C1 YZRHJTFBPBFLSM-ALGFLVEBSA-N 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 3
- 208000017667 Chronic Disease Diseases 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000001925 catabolic effect Effects 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000014311 Cushing syndrome Diseases 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010029748 Noonan syndrome Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 206010072610 Skeletal dysplasia Diseases 0.000 claims description 2
- 208000026928 Turner syndrome Diseases 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 201000008980 hyperinsulinism Diseases 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000009602 intrauterine growth Effects 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- QJMMSUIZYUKFLO-UHFFFAOYSA-N n-methyl-2-naphthalen-2-ylethanamine Chemical compound C1=CC=CC2=CC(CCNC)=CC=C21 QJMMSUIZYUKFLO-UHFFFAOYSA-N 0.000 claims description 2
- 210000000963 osteoblast Anatomy 0.000 claims description 2
- 230000016087 ovulation Effects 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 230000017363 positive regulation of growth Effects 0.000 claims description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
- 230000000541 pulsatile effect Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- ZENKPXNCYVHZAL-INFWYBNYSA-N (3R)-4-[(E)-5-amino-5-methylhex-2-enoyl]-3-(naphthalen-2-ylmethyl)-1-(1-phenylethyl)piperazin-2-one Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(CC1)C(=O)\C=C\CC(C)(C)N)N1C(C)C1=CC=CC=C1 ZENKPXNCYVHZAL-INFWYBNYSA-N 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- HZPKBWLLSZCROS-AHKGRUIUSA-N (2r)-2-[[(e)-5-amino-5-methylhex-2-enoyl]-methylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C[C@@H](N(C)C(=O)\C=C\CC(C)(C)N)C(O)=O)=CC=C21 HZPKBWLLSZCROS-AHKGRUIUSA-N 0.000 claims 1
- PKVGEUCCBFDWEF-YBLZLUOVSA-N (e)-5-[[(2r)-2-hydroxypropyl]amino]-n,5-dimethyl-n-[(2r)-1-[methyl(2-phenylethyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)/C=C/CC(C)(C)NC[C@H](O)C)N(C)CCC1=CC=CC=C1 PKVGEUCCBFDWEF-YBLZLUOVSA-N 0.000 claims 1
- XYTIFQRQPIRQKL-LNFHGXOESA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl(2-thiophen-2-ylethyl)amino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]hex-2-enamide Chemical compound O=C([C@@H](CC=1C=CC(=CC=1)C=1C=CC=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)N(C)CCC1=CC=CS1 XYTIFQRQPIRQKL-LNFHGXOESA-N 0.000 claims 1
- NKTMLMJWHNDQDF-VISBSAOHSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl(2-thiophen-2-ylethyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)N(C)CCC1=CC=CS1 NKTMLMJWHNDQDF-VISBSAOHSA-N 0.000 claims 1
- ZKOVFTZDSOPHPD-VAACGYSUSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl(3-phenylpropyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)N(C)CCCC1=CC=CC=C1 ZKOVFTZDSOPHPD-VAACGYSUSA-N 0.000 claims 1
- BPSKBOYVECHQRJ-LNFHGXOESA-N (e)-5-amino-n-[(2r)-1-(3,4-dihydro-1h-isoquinolin-2-yl)-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound C1CC2=CC=CC=C2CN1C(=O)[C@H](N(C)C(=O)\C=C\CC(C)(C)N)CC1=CC=C(C=CC=C2)C2=C1 BPSKBOYVECHQRJ-LNFHGXOESA-N 0.000 claims 1
- AGXMIHNERLMKMK-GUWJCNJBSA-N (e)-5-amino-n-[(2r)-1-[2-benzyl-2-(ethylcarbamoyl)hydrazinyl]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)NN(C(=O)NCC)CC1=CC=CC=C1 AGXMIHNERLMKMK-GUWJCNJBSA-N 0.000 claims 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 230000010072 bone remodeling Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 230000008717 functional decline Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000011218 segmentation Effects 0.000 claims 1
- 230000002992 thymic effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 563
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 412
- 239000000243 solution Substances 0.000 description 232
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 181
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 178
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 169
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 158
- 239000002904 solvent Substances 0.000 description 117
- 238000005160 1H NMR spectroscopy Methods 0.000 description 104
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 104
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 88
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 87
- 235000019341 magnesium sulphate Nutrition 0.000 description 87
- 239000011541 reaction mixture Substances 0.000 description 86
- 239000000377 silicon dioxide Substances 0.000 description 86
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 80
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 74
- 239000012044 organic layer Substances 0.000 description 73
- 235000017557 sodium bicarbonate Nutrition 0.000 description 72
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 72
- 239000012043 crude product Substances 0.000 description 71
- 239000008346 aqueous phase Substances 0.000 description 67
- 239000003480 eluent Substances 0.000 description 62
- 238000003818 flash chromatography Methods 0.000 description 58
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 52
- 229920006395 saturated elastomer Polymers 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 41
- 239000007787 solid Substances 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- 229960000583 acetic acid Drugs 0.000 description 36
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 31
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 31
- 239000012071 phase Substances 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 239000002253 acid Substances 0.000 description 30
- 238000001819 mass spectrum Methods 0.000 description 30
- 239000007864 aqueous solution Substances 0.000 description 29
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 29
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 29
- 238000004128 high performance liquid chromatography Methods 0.000 description 28
- 238000004587 chromatography analysis Methods 0.000 description 26
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 238000000746 purification Methods 0.000 description 23
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 23
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 21
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 19
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 14
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 10
- BOSXPQNYNMINOQ-MGUPHCMFSA-N (e)-5-amino-n-[(2r)-1-[2-[2-(methanesulfonamido)phenyl]ethyl-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)N(C)CCC1=CC=CC=C1NS(C)(=O)=O BOSXPQNYNMINOQ-MGUPHCMFSA-N 0.000 description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 9
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 8
- 238000005191 phase separation Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 8
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 7
- 230000001817 pituitary effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000052 vinegar Substances 0.000 description 7
- 235000021419 vinegar Nutrition 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 6
- WTGCDTYRZPRKIL-MRXNPFEDSA-N (2r)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C[C@@H](N(C)C(=O)OC(C)(C)C)C(O)=O)=CC=C21 WTGCDTYRZPRKIL-MRXNPFEDSA-N 0.000 description 5
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 5
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003610 charcoal Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002808 molecular sieve Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical class CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001024304 Mino Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 102100022831 Somatoliberin Human genes 0.000 description 4
- 101710142969 Somatoliberin Proteins 0.000 description 4
- 229920000535 Tan II Polymers 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000003963 dichloro group Chemical group Cl* 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- KPUIBITXUURMJF-BQYQJAHWSA-N (e)-5-methyl-5-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]hex-2-enoic acid Chemical compound CC(C)(C)OC(=O)N(C)C(C)(C)C\C=C\C(O)=O KPUIBITXUURMJF-BQYQJAHWSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- PTZJZLIXPAFDIG-UHFFFAOYSA-N 1-amino-1-benzyl-3-ethylurea Chemical compound CCNC(=O)N(N)CC1=CC=CC=C1 PTZJZLIXPAFDIG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100022749 Aminopeptidase N Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010049990 CD13 Antigens Proteins 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000005367 Carboxypeptidases Human genes 0.000 description 3
- 108010006303 Carboxypeptidases Proteins 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- ITDJKCJYYAQMRO-UHFFFAOYSA-L rhodium(2+);diacetate Chemical compound [Rh+2].CC([O-])=O.CC([O-])=O ITDJKCJYYAQMRO-UHFFFAOYSA-L 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- YWSXTMBDIBZHBB-UHFFFAOYSA-N tert-butyl n-but-3-enylcarbamate Chemical compound CC(C)(C)OC(=O)NCCC=C YWSXTMBDIBZHBB-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 2
- GCXQPGVKIIZBCV-HSZRJFAPSA-N (2r)-n-[2-[2-(2-hydroxyethoxy)phenyl]ethyl]-n-methyl-2-(methylamino)-3-naphthalen-2-ylpropanamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)N(C)CCC1=CC=CC=C1OCCO GCXQPGVKIIZBCV-HSZRJFAPSA-N 0.000 description 2
- ASLTYORRFWSCEY-JOCHJYFZSA-N (2r)-n-methyl-2-(methylamino)-3-(4-phenylphenyl)-n-(2-thiophen-2-ylethyl)propanamide Chemical compound C([C@@H](NC)C(=O)N(C)CCC=1SC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 ASLTYORRFWSCEY-JOCHJYFZSA-N 0.000 description 2
- MDEZSPBZNGJMIK-HSZRJFAPSA-N (2r)-n-methyl-2-(methylamino)-3-naphthalen-2-yl-n-(3-phenylpropyl)propanamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)N(C)CCCC1=CC=CC=C1 MDEZSPBZNGJMIK-HSZRJFAPSA-N 0.000 description 2
- HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 2
- HAAUASBAIUJHAN-LXOXETEGSA-N (4s)-4-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-(carboxymethylamino)-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol- Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CN=CN1 HAAUASBAIUJHAN-LXOXETEGSA-N 0.000 description 2
- FTHUQCQZQRXJLF-HWKANZROSA-N (e)-5-methylhex-2-enoic acid Chemical compound CC(C)C\C=C\C(O)=O FTHUQCQZQRXJLF-HWKANZROSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- DJQVPXPEXAWGRE-UHFFFAOYSA-N 2,3-dihydrotriazolo[4,5-b]pyridin-7-one Chemical compound O=C1C=CN=C2NNN=C12 DJQVPXPEXAWGRE-UHFFFAOYSA-N 0.000 description 2
- MUIJITJDBKKILF-UHFFFAOYSA-N 2-[2-[2-(methylamino)ethyl]phenoxy]ethanol Chemical compound CNCCC1=CC=CC=C1OCCO MUIJITJDBKKILF-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- XSIYHTUHOZAWFQ-UHFFFAOYSA-N 2-phenylmethoxyfuran Chemical compound C=1C=CC=CC=1COC1=CC=CO1 XSIYHTUHOZAWFQ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 2
- 101710202385 Growth hormone secretagogue receptor type 1 Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- HBWLGAIQNVAFGS-UHFFFAOYSA-N n-(2-thiophen-2-ylethyl)formamide Chemical compound O=CNCCC1=CC=CS1 HBWLGAIQNVAFGS-UHFFFAOYSA-N 0.000 description 2
- IJELUJLKMVZBTA-UHFFFAOYSA-N n-[2-[2-(methylamino)ethyl]phenyl]methanesulfonamide Chemical compound CNCCC1=CC=CC=C1NS(C)(=O)=O IJELUJLKMVZBTA-UHFFFAOYSA-N 0.000 description 2
- ONHWNARPSWLBLK-UHFFFAOYSA-N n-methyl-2-(2-nitrophenyl)acetamide Chemical compound CNC(=O)CC1=CC=CC=C1[N+]([O-])=O ONHWNARPSWLBLK-UHFFFAOYSA-N 0.000 description 2
- JKFQTSXUKNGFQF-UHFFFAOYSA-N n-methyl-2-(2-nitrophenyl)ethanamine Chemical compound CNCCC1=CC=CC=C1[N+]([O-])=O JKFQTSXUKNGFQF-UHFFFAOYSA-N 0.000 description 2
- IKSCPAWBLQEUAG-UHFFFAOYSA-N n-methyl-2-thiophen-2-ylethanamine Chemical compound CNCCC1=CC=CS1 IKSCPAWBLQEUAG-UHFFFAOYSA-N 0.000 description 2
- MLHBZVFOTDJTPK-UHFFFAOYSA-N n-methyl-3-phenylpropan-1-amine Chemical compound CNCCCC1=CC=CC=C1 MLHBZVFOTDJTPK-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 229960000208 pralmorelin Drugs 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000000580 secretagogue effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 2
- QXOGOBCTWHELDJ-AJFHRXSQSA-N tert-butyl n-[(e)-2-methyl-6-[methyl-[(2r)-1-[methyl(2-thiophen-2-ylethyl)amino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]amino]-6-oxohex-4-en-2-yl]carbamate Chemical compound O=C([C@@H](CC=1C=CC(=CC=1)C=1C=CC=CC=1)N(C)C(=O)\C=C\CC(C)(C)NC(=O)OC(C)(C)C)N(C)CCC1=CC=CS1 QXOGOBCTWHELDJ-AJFHRXSQSA-N 0.000 description 2
- XDKBZGVDRJSORA-BMXGUMNWSA-N tert-butyl n-[1-[3-[methyl-[(2r)-1-[methyl(2-thiophen-2-ylethyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]phenyl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C)C1=CC=CC(C(=O)N(C)[C@H](CC=2C=C3C=CC=CC3=CC=2)C(=O)N(C)CCC=2SC=CC=2)=C1 XDKBZGVDRJSORA-BMXGUMNWSA-N 0.000 description 2
- KJDSVUQKZBQRBA-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(2-nitrophenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCC1=CC=CC=C1[N+]([O-])=O KJDSVUQKZBQRBA-UHFFFAOYSA-N 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- BNJMRELGMDUDDB-UHFFFAOYSA-N $l^{1}-sulfanylbenzene Chemical compound [S]C1=CC=CC=C1 BNJMRELGMDUDDB-UHFFFAOYSA-N 0.000 description 1
- FRYOCKYIGKFINL-MRVPVSSYSA-N (2R)-2-[tert-butyl(dimethyl)silyl]oxypropan-1-ol Chemical compound C[C@H](CO)O[Si](C)(C)C(C)(C)C FRYOCKYIGKFINL-MRVPVSSYSA-N 0.000 description 1
- WYDLTAMSCOSRJJ-JOCHJYFZSA-N (2r)-1-(3,4-dihydro-1h-isoquinolin-2-yl)-2-(methylamino)-3-naphthalen-2-ylpropan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)[C@H](NC)CC1=CC=C(C=CC=C2)C2=C1 WYDLTAMSCOSRJJ-JOCHJYFZSA-N 0.000 description 1
- XRBFRWVSTGFFCB-CYBMUJFWSA-N (2r)-2-(methylamino)-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C[C@@H](NC)C(O)=O)=CC=C21 XRBFRWVSTGFFCB-CYBMUJFWSA-N 0.000 description 1
- NBVVKAUSAGHTSU-QGZVFWFLSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C[C@@H](NC(=O)OC(C)(C)C)C(O)=O)=CC=C1C1=CC=CC=C1 NBVVKAUSAGHTSU-QGZVFWFLSA-N 0.000 description 1
- URKWHOVNPHQQTM-OAHLLOKOSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C[C@@H](NC(=O)OC(C)(C)C)C(O)=O)=CC=C21 URKWHOVNPHQQTM-OAHLLOKOSA-N 0.000 description 1
- YRRRZHCEMUVTQD-DHIUTWEWSA-N (2r)-2-[[(2r)-2-amino-3-naphthalen-2-ylpropyl]-(2-chloroacetyl)amino]-n-methyl-3-phenylpropanamide Chemical compound C([C@H](C(=O)NC)N(C[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)CCl)C1=CC=CC=C1 YRRRZHCEMUVTQD-DHIUTWEWSA-N 0.000 description 1
- BVRKOQJETMBIDK-SECBINFHSA-N (2r)-2-amino-n-methyl-3-phenylpropanamide Chemical compound CNC(=O)[C@H](N)CC1=CC=CC=C1 BVRKOQJETMBIDK-SECBINFHSA-N 0.000 description 1
- QHPYBXGVHANYTB-XMMPIXPASA-N (2r)-n-[2-[2-(3-hydroxypropoxy)phenyl]ethyl]-n-methyl-2-(methylamino)-3-naphthalen-2-ylpropanamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)N(C)CCC1=CC=CC=C1OCCCO QHPYBXGVHANYTB-XMMPIXPASA-N 0.000 description 1
- XRDRGRQACLOLKF-HSZRJFAPSA-N (2r)-n-[2-[2-(methanesulfonamido)phenyl]ethyl]-n-methyl-2-(methylamino)-3-naphthalen-2-ylpropanamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)N(C)CCC1=CC=CC=C1NS(C)(=O)=O XRDRGRQACLOLKF-HSZRJFAPSA-N 0.000 description 1
- PHWYHLZCMCWUJY-JOCHJYFZSA-N (2r)-n-methyl-2-(methylamino)-3-naphthalen-2-yl-n-(2-phenylethyl)propanamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)N(C)CCC1=CC=CC=C1 PHWYHLZCMCWUJY-JOCHJYFZSA-N 0.000 description 1
- GRUPUGMHKPCNFQ-HXUWFJFHSA-N (2r)-n-methyl-2-(methylamino)-3-naphthalen-2-yl-n-(2-thiophen-2-ylethyl)propanamide Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)N(C)CCC1=CC=CS1 GRUPUGMHKPCNFQ-HXUWFJFHSA-N 0.000 description 1
- ZZQVJGVPPDSLDW-DHIUTWEWSA-N (2r)-n-methyl-2-[(5r)-5-(naphthalen-2-ylmethyl)-2-oxopiperazin-1-yl]-3-phenylpropanamide Chemical compound C([C@H](C(=O)NC)N1C(CN[C@H](CC=2C=C3C=CC=CC3=CC=2)C1)=O)C1=CC=CC=C1 ZZQVJGVPPDSLDW-DHIUTWEWSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- MYLLYGVXNGGEDL-CQSZACIVSA-N (3r)-3-(naphthalen-2-ylmethyl)piperazin-2-one Chemical compound O=C1NCCN[C@@H]1CC1=CC=C(C=CC=C2)C2=C1 MYLLYGVXNGGEDL-CQSZACIVSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- SWGZHHCRMZDRSN-BTJKTKAUSA-N (Z)-but-2-enedioic acid 1-phenoxypropan-2-ylhydrazine Chemical compound OC(=O)\C=C/C(O)=O.NNC(C)COC1=CC=CC=C1 SWGZHHCRMZDRSN-BTJKTKAUSA-N 0.000 description 1
- NRPOEGFAIJAQIE-VOTSOKGWSA-N (e)-5-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]hex-2-enoic acid Chemical compound CC(C)(C)OC(=O)NC(C)(C)C\C=C\C(O)=O NRPOEGFAIJAQIE-VOTSOKGWSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- QLYPHTMKMPIJNG-UHFFFAOYSA-N 1-naphthalen-2-ylpropan-1-one Chemical compound C1=CC=CC2=CC(C(=O)CC)=CC=C21 QLYPHTMKMPIJNG-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- FSNCWQAANDOQAW-UHFFFAOYSA-N 2-(2-hydroxyphenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC=CC=C1O FSNCWQAANDOQAW-UHFFFAOYSA-N 0.000 description 1
- 125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- MDTMSMLZHVQGPA-UHFFFAOYSA-N 2-[2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]acetic acid Chemical compound CC(C)(C)OC(=O)NC(C)(C)COCC(O)=O MDTMSMLZHVQGPA-UHFFFAOYSA-N 0.000 description 1
- LXXMRJSJFZZOHU-VIFPVBQESA-N 2-[[(2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]methoxy]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1COCC(O)=O LXXMRJSJFZZOHU-VIFPVBQESA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- KBMDBLCFKPRPOC-UHFFFAOYSA-N 2-bromo-3,3,3-trifluoro-2-(trifluoromethyl)propanenitrile Chemical compound FC(F)(F)C(Br)(C#N)C(F)(F)F KBMDBLCFKPRPOC-UHFFFAOYSA-N 0.000 description 1
- XUXJHBAJZQREDB-UHFFFAOYSA-N 2-methylbutanamide Chemical compound CCC(C)C(N)=O XUXJHBAJZQREDB-UHFFFAOYSA-N 0.000 description 1
- INIORXKZIAURPD-UHFFFAOYSA-N 2-methylpent-4-en-2-ylcarbamic acid Chemical compound C=CCC(C)(C)NC(O)=O INIORXKZIAURPD-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- HVLUYXIJZLDNIS-UHFFFAOYSA-N 2-thiophen-2-ylethanamine Chemical compound NCCC1=CC=CS1 HVLUYXIJZLDNIS-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- JWYITCUSPYOBSX-UHFFFAOYSA-N 3-[1-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NC(C)C1=CC=CC(C(O)=O)=C1 JWYITCUSPYOBSX-UHFFFAOYSA-N 0.000 description 1
- SBCFGFDAZCTSRH-UHFFFAOYSA-N 3-acetylbenzonitrile Chemical compound CC(=O)C1=CC=CC(C#N)=C1 SBCFGFDAZCTSRH-UHFFFAOYSA-N 0.000 description 1
- LHJVMOIOTPJSLS-UHFFFAOYSA-N 3-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC(C)(C)CC(O)=O LHJVMOIOTPJSLS-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JKTORXLUQLQJCM-UHFFFAOYSA-N 4-phosphonobutylphosphonic acid Chemical compound OP(O)(=O)CCCCP(O)(O)=O JKTORXLUQLQJCM-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- UCYNJUHJNFGICB-DIPNUNPCSA-N 9h-fluoren-9-ylmethyl n-[2-[2-[2-[methyl-[(2r)-2-(methylamino)-3-naphthalen-2-ylpropanoyl]amino]ethyl]anilino]-2-oxoethyl]carbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NCC(=O)NC1=CC=CC=C1CCN(C)C(=O)[C@H](NC)CC1=CC=C(C=CC=C2)C2=C1 UCYNJUHJNFGICB-DIPNUNPCSA-N 0.000 description 1
- 241000114726 Acetes Species 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- RWDFNVCMKMESHU-UHFFFAOYSA-N CC(C)(C)OBO Chemical compound CC(C)(C)OBO RWDFNVCMKMESHU-UHFFFAOYSA-N 0.000 description 1
- IYJISMQKTNLEBJ-VISBSAOHSA-N CC(C)(C/C=C/C(=O)N(C)[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)CCC3=CC=CS3)NC(=O)O Chemical compound CC(C)(C/C=C/C(=O)N(C)[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)CCC3=CC=CS3)NC(=O)O IYJISMQKTNLEBJ-VISBSAOHSA-N 0.000 description 1
- KLPYIKKVMQTYME-GPIXMLASSA-N CC1[C@@](N(CCN1)C(=O)OC(C)(C)C)(CCC2=CC=CC(=O)C2)C3=CC4=CC=CC=C4C=C3 Chemical compound CC1[C@@](N(CCN1)C(=O)OC(C)(C)C)(CCC2=CC=CC(=O)C2)C3=CC4=CC=CC=C4C=C3 KLPYIKKVMQTYME-GPIXMLASSA-N 0.000 description 1
- BCPRXBKJSBHNSG-UHFFFAOYSA-N CNC(CC1=C(C=CC=C1)OC(C1=CC=CC=C1)=O)=O Chemical compound CNC(CC1=C(C=CC=C1)OC(C1=CC=CC=C1)=O)=O BCPRXBKJSBHNSG-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001072332 Monia Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- QJFLCDSFZWVZMV-UHFFFAOYSA-N OC(=O)C1=CC=NC2=C1N=NN2O Chemical compound OC(=O)C1=CC=NC2=C1N=NN2O QJFLCDSFZWVZMV-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 241000051616 Ulmus minor Species 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- RIUHTCYCVSHAPY-UHFFFAOYSA-N [2-[2-[2-(methylamino)ethyl]anilino]-2-oxoethyl]carbamic acid Chemical compound CNCCC1=CC=CC=C1NC(=O)CNC(O)=O RIUHTCYCVSHAPY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VWSRWGFGAAKTQG-UHFFFAOYSA-N ammonium benzoate Chemical compound [NH4+].[O-]C(=O)C1=CC=CC=C1 VWSRWGFGAAKTQG-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940087827 biolon Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- IHIBPMKGKJSBKT-UHFFFAOYSA-N but-3-enyl carbamate Chemical compound NC(=O)OCCC=C IHIBPMKGKJSBKT-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- QMYJQVPZCRLRHJ-UHFFFAOYSA-N ethyl 2-[2-[2-(methylamino)-2-oxoethyl]phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=CC=C1CC(=O)NC QMYJQVPZCRLRHJ-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- OXZOLXJZTSUDOM-UHFFFAOYSA-N fluoro 2,2,2-trifluoroacetate Chemical compound FOC(=O)C(F)(F)F OXZOLXJZTSUDOM-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- DTMJCJINCCWTTG-UHFFFAOYSA-N n-(3-phenylpropyl)formamide Chemical compound O=CNCCCC1=CC=CC=C1 DTMJCJINCCWTTG-UHFFFAOYSA-N 0.000 description 1
- AMHHACRZBSECQT-UHFFFAOYSA-N n-(3-phenylpropyl)propanamide Chemical compound CCC(=O)NCCCC1=CC=CC=C1 AMHHACRZBSECQT-UHFFFAOYSA-N 0.000 description 1
- CBHYFZKCNVQNMV-UHFFFAOYSA-N n-[2-[2-(methylamino)ethyl]phenyl]benzenesulfonamide Chemical compound CNCCC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=C1 CBHYFZKCNVQNMV-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- BCHHEBKQBKFUNW-UHFFFAOYSA-N n-ethyl-n'-propylmethanediimine;hydrochloride Chemical compound Cl.CCCN=C=NCC BCHHEBKQBKFUNW-UHFFFAOYSA-N 0.000 description 1
- XWCCTMBMQUCLSI-UHFFFAOYSA-N n-ethyl-n-propylpropan-1-amine Chemical compound CCCN(CC)CCC XWCCTMBMQUCLSI-UHFFFAOYSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- VYKHIPPRCFLHGC-UHFFFAOYSA-N n-methyl-2-(2-phenylmethoxyphenyl)ethanamine Chemical compound CNCCC1=CC=CC=C1OCC1=CC=CC=C1 VYKHIPPRCFLHGC-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- CCVYRRGZDBSHFU-UHFFFAOYSA-N o-Hydroxyphenylacetic acid Natural products OC(=O)CC1=CC=CC=C1O CCVYRRGZDBSHFU-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002072 seryl group Chemical group 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- NUMQCACRALPSHD-UHFFFAOYSA-N tert-Butyl ethyl ether Natural products CCOC(C)(C)C NUMQCACRALPSHD-UHFFFAOYSA-N 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NPSILQRSKNCBKB-NSHDSACASA-N tert-butyl (2s)-2-[(2-ethoxy-2-oxoethoxy)methyl]pyrrolidine-1-carboxylate Chemical compound CCOC(=O)COC[C@@H]1CCCN1C(=O)OC(C)(C)C NPSILQRSKNCBKB-NSHDSACASA-N 0.000 description 1
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
- IFSLNNOKVHEUOZ-UHFFFAOYSA-N tert-butyl n-(2-methylpent-4-en-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(C)CC=C IFSLNNOKVHEUOZ-UHFFFAOYSA-N 0.000 description 1
- ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 1
- OPVJBJKJBHTNCE-UHFFFAOYSA-N tert-butyl n-(benzylamino)carbamate Chemical compound CC(C)(C)OC(=O)NNCC1=CC=CC=C1 OPVJBJKJBHTNCE-UHFFFAOYSA-N 0.000 description 1
- NTMBPPQFUQUVPI-RUZDIDTESA-N tert-butyl n-[(2r)-1-(3,4-dihydro-1h-isoquinolin-2-yl)-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methylcarbamate Chemical compound C1CC2=CC=CC=C2CN1C(=O)[C@H](N(C)C(=O)OC(C)(C)C)CC1=CC=C(C=CC=C2)C2=C1 NTMBPPQFUQUVPI-RUZDIDTESA-N 0.000 description 1
- WZRJBZKIAFYJPL-HHHXNRCGSA-N tert-butyl n-[(2r)-1-[2-[2-(3-hydroxypropoxy)phenyl]ethyl-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methylcarbamate Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)OC(C)(C)C)N(C)CCC1=CC=CC=C1OCCCO WZRJBZKIAFYJPL-HHHXNRCGSA-N 0.000 description 1
- YQMLCZHYFNJMBX-JWQCQUIFSA-N tert-butyl n-[(2r)-1-[[(2r)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-ylpropan-2-yl]carbamate Chemical compound C([C@H](C(=O)NC)NC[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 YQMLCZHYFNJMBX-JWQCQUIFSA-N 0.000 description 1
- ZQYYWEQDOVXIMF-PTBVXMEYSA-N tert-butyl n-[(e)-2-methyl-6-[methyl-[(2r)-1-[methyl(3-phenylpropyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-6-oxohex-4-en-2-yl]carbamate Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)NC(=O)OC(C)(C)C)N(C)CCCC1=CC=CC=C1 ZQYYWEQDOVXIMF-PTBVXMEYSA-N 0.000 description 1
- FRHGMPRMZCJWTD-ODMPMCBYSA-N tert-butyl n-[(e)-6-[[(2r)-1-[2-[2-(2-hydroxyethoxy)phenyl]ethyl-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-methylamino]-2-methyl-6-oxohex-4-en-2-yl]carbamate Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)NC(=O)OC(C)(C)C)N(C)CCC1=CC=CC=C1OCCO FRHGMPRMZCJWTD-ODMPMCBYSA-N 0.000 description 1
- ZWIZXBZHEPLEBS-ODMPMCBYSA-N tert-butyl n-[(e)-6-[[(2r)-1-[2-[2-[(2-aminoacetyl)amino]phenyl]ethyl-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-methylamino]-2-methyl-6-oxohex-4-en-2-yl]carbamate Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)NC(=O)OC(C)(C)C)N(C)CCC1=CC=CC=C1NC(=O)CN ZWIZXBZHEPLEBS-ODMPMCBYSA-N 0.000 description 1
- OGMCENUNFXNYPJ-UHFFFAOYSA-N tert-butyl n-[2-(2-aminophenyl)ethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCC1=CC=CC=C1N OGMCENUNFXNYPJ-UHFFFAOYSA-N 0.000 description 1
- WJOZTIPIGUWXHU-UHFFFAOYSA-N tert-butyl n-[2-[2-(benzenesulfonamido)phenyl]ethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=C1 WJOZTIPIGUWXHU-UHFFFAOYSA-N 0.000 description 1
- AOFLWMYKSYDQSP-JGCGQSQUSA-N tert-butyl n-[[3-[[(2r)-1-[2-[2-(2-hydroxyethoxy)phenyl]ethyl-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]phenyl]methyl]carbamate Chemical compound O=C([C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)C=1C=C(CNC(=O)OC(C)(C)C)C=CC=1)N(C)CCC1=CC=CC=C1OCCO AOFLWMYKSYDQSP-JGCGQSQUSA-N 0.000 description 1
- OTDMLXZSLSKNMT-UHFFFAOYSA-N tert-butyl n-[benzyl(ethylcarbamoyl)amino]carbamate Chemical compound CC(C)(C)OC(=O)NN(C(=O)NCC)CC1=CC=CC=C1 OTDMLXZSLSKNMT-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- QVXRETVKPOPWNI-RUZDIDTESA-N tert-butyl n-methyl-n-[(2r)-1-[methyl(2-thiophen-2-ylethyl)amino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]carbamate Chemical compound O=C([C@@H](CC=1C=CC(=CC=1)C=1C=CC=CC=1)N(C)C(=O)OC(C)(C)C)N(C)CCC1=CC=CS1 QVXRETVKPOPWNI-RUZDIDTESA-N 0.000 description 1
- RKBLAXHVQYRXFV-UHFFFAOYSA-N tert-butyl n-methyl-n-propylcarbamate Chemical compound CCCN(C)C(=O)OC(C)(C)C RKBLAXHVQYRXFV-UHFFFAOYSA-N 0.000 description 1
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
- WVRJUMZHKISIJD-UHFFFAOYSA-N tetraazanium;disulfate Chemical compound [NH4+].[NH4+].[NH4+].[NH4+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O WVRJUMZHKISIJD-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000005313 thymus development Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.一般式Iの化合物 式I (式中: AはA1又はA2であり; GはG1又はG2であり; Dは水素、−O−(CH2)K−R5a、 であり; ここで、R5,R6,R7,R8及びR9は独立して水素、ハロゲン、アリール、 C1−C6アルキル又はC1-6アルコキシであり; R5aは水素、任意的にハロゲンもしくはC1-6アルキルで置換されたアリール 、又は任意的にハロゲンもしくはC1-6アルキルで置換されたC1-6アルキルであ り; Kは0,1,2又は3であり; Eは水素、−O−(CH2)1−R10a、 であり、ここで R10,R11,R12,R13及びR14は独立して水素、ハロゲン、アリール、C1- 6 −アルキル、C1-6−アルコキシ、−CONR15R16,−(CH2)v−NR15SO2R17,−(CH2 )v−NR15COR16,−(CH2)v−OR17,−(CH2)v−OCOR16,−CH(R15)R16,−(CH2 )v−NR15−CS−NR16R18,−(CH2)v−NR15−CO−NR16R18, であり、ここで X1は−N(R19)−,−O−又は−S−であり; X2は−C(R20)=又は−N=であり; X3は−C(R21)=又は−N=であり; X4は−C(R22)=又は−N=であり; R2及びR10は一緒になって−CH2−又は−CH2−CH2−を形成してよく; R19は水素又は任意的にアリールで置換されたC1-6アルキルであり; R20,R21及びR22は独立して水素、−COOR23,−CONR24R25,−(CH2)w NR24 R25,−(CH2)wOR23,−(CH2)w R23又はハロゲンであり; R15,R16,R23,R24及びR25は独立して水素、又は任意的にハロゲン、− N(R26)R27、ヒドロキシル、C1-6アルコキシ、C1-6アルコキシカルボニル 、C1-6アルキル−カルボニルオキシもしくはアリールにより置換されたC1-6ア ルキルであるか、又は R16は であり、ここで Q1は−CH<又は−N<であり; T1及びJ1は独立して−CH2−,−CO−,−O−,−S−,−NR28−又は原子 価結合であり; ここでR28は水素又は直鎖もしくは枝分れC1-6アルキルであり; t及びuは独立して0,1,2,3又は4であり; R17は任意的にヒドロキシルもしくはアリールにより置換されたC1-6アルキ ル又はフェニルであり; R18はC1-6アルキルであり; R26及びR27は独立して水素又はC1-6アルキルであり; v及びwは独立して0,1,2又は3であり; R10aは水素、任意的にハロゲンもしくはC1-6アルキルにより置換されたアリ ール、又は任意的にハロゲンもしくはC1-6アルキルにより置換されたC1-6アル キルであり; lは0,1,2又は3であり; A1は であり、ここで R29,R30,R31,R32,R33,R34,R35及びR36は独立して水素又は任意 的にハロゲン、アミノ、ヒドロキシもしくはアリールにより置換されたC1-6ア ルキルであり; R33及びR34,R33及びR35、又はR34及びR35は任意的に−(CH2)i−Z−(C H2)i−を形成してよく、ここでi及びjは独立して1又は2であり、そしてZは −O−,−S−又は原子価結合であり; n,m及びqは独立して0,1,2又は3であり; o及びpは独立して0又は1であり; Mは−CR37=CR38−,−O−,−S−又は原子価結合であり; R37及びR38は独立して水素、又は任意的にアリールで置換されたC1-6アル キルであり; A2は であり、ここで R29,R30,R31,R32,R33,R34,R35及びR36は独立して水素又は任意 的にハロゲン、アミノ、ヒドロキシルもしくはアリールにより置換されたC1-6 アルキルであり; R33及びR34,R33及びR35、又はR34及びR35は任意的に−(CH2)i−Z−(C H2)i−を形成してよく、ここでi及びjは独立して1又は2であり、そしてZは −O−,−S−又は原子価結合であり; n,m及びqは独立して0,1,2又は3であり; o及びpは独立して0又は1であり; Mは−CR37=CR38−,−O−又は−S−であり; R37及びR38は独立して水素、又は任意的にアリールで置換されたC1-6アル キルであり; G1は水素、ハロゲン、アリール、C1-6アルキル、C1-6アルコキシ、−CONR3 9 R40,−(CH2)c−NR39SO2R41,−(CH2)c−NR39COR40,−(CH2)c−ORO41,−(CH2 )c−OCOR40,−CH(R39)R40,−CON39−NR40R42,−(CH2)c−NR39−CS−NR40 R42,−(CH2)e−NR39−CO−NR40R42, であり、ここで X5は−N(R43)−,−O−又は−S−であり; X6は−C(R44)=又は−N=であり; X7は−C(R45)=又は−N=であり; X8は−C(R46)=又は−N=であり; R43は水素又は任意的にアリールにより置換されたC1-6アルキルであり; R44,R45及びR46は独立して水素、−COOR47,−CONR48R49,−(CH2)4NR48 R49,−(CH2)fOR47,−(CH2)fR47又はハロゲンであり; R39,R40,R47,R48及びR49は独立して水素又は任意的にハロゲンで置換 されたC1-6アルキル、 −N(R50)R51、ヒドロキシル、C1-6アルコキシ、C1-6アルコキシカルボ ニル、C1-6アルキルカルボニルオキシ又はアリールであるか、又は R40は であり、ここで Q2は−CH<又は−N<であり; J2及びT2は独立して−CH2−,−CO−,−O−,−S−,−NR52−又は原子 価結合であり; ここでR52は水素又はC1-6アルキルであり; x及びyは独立して0,1,2,3又は4であり; R41はアリールで置換されたC1-6アルキルであり; R42はC1-6、アルキルであり; R50及びR51は独立して水素又はC1-6アルキルであり; e及びfは独立して0,1,2又は3であり; G2は水素又はC1-6アルキルであり; R1は水素又はC1-6アルキルであり; R2は水素、−C(=O)−R54又はC1-6アルキルであり; R1及びR2は一緒になって次のタイプの架橋を形成してよく; ここでR55及びR56は独立して水素、任意的にヒドロキシル、C1-6アルコキ シル又はアリールで置換されたC1-6アルキルであり; R55及びR56は一緒になって=O又は=Sを形成してよく; c及びdは独立して0,1又は2であり; c+dは0,1又は2であり; R54は水素又はC1-6アルキルであり; R3及びR4は水素、任意的にヒドロキシルC1-6アルコキシル、ハロゲン又は アリールで置換されたC1-6アルキルであり; R3及びR4は一緒になって=S又は=Oを形成してよく; L1はCR57又はNであり; L2はCR58又はNであり; R57及びR58は独立して水素、任意的にヒドロキシル、ハロゲン、C1-6アル コキシル又はアリールで置換されたC1-6アルキルであり; a及びbは独立して、0,1,2又は3である; 但し、 GがG2であり、そしてL1がCR55であり、そしてL2がCR56のとき、AはA2で あり; GがG1であり、そしてL1がCR55であり、そしてL2がCR56のとき、AはA1で あり、そしてR2は−C(=O)−R54であるか、又はR1及びR2は一緒になっ て次のタイプの架橋を形成しており: L1又はL2のいづれかがNのとき、GはG1であり、そしてAはA1である) 又はその薬理学的に許容される塩。 2.一般式Iの化合物 (式中: AはA1又はA2であり; GはG1又はG2であり; Dは水素、−O−(CH2)k−R5a、 であり; ここで、R5,R6,R7,R8及びR9は独立して水素、ハロゲン、アリール、 C1−C6、アルキル又はC1-6、アルコキシであり; R5aは水素、アリール、又はC1-6アルキルであり; kは0,1,2又は3であり; Eは水素、−O−(CH2)1−R10a、 であり、ここで R10,R11,R12,R13及びR14は独立して水素、ハロゲン、アリール、C1- 6 −アルキル、C1-6−アルコキシ、−CONR15R16,−(CH2)v−NR15SO2R17,−(CH2 )v−NR15COR16,−(CH2)v−OR17,−(CH2)v−OCOR16,−CH(R15)R16,−(C H2)v−NR15−CS−NR16R18,−(CH2)v−NR15−CO−NR16R18, であり、ここで X1は−N(R19)−,−O−又は−S−であり; X2は−C(R20)=又は−N=であり; X3は−C(R21)=又は−N=であり; X4は−C(R22)=又は−N=であり; R19は水素又は任意的にアリールで置換されたC1-6アルキルであり; R20,R21及びR22は独立して水素、−COOR23,−CONR24R25,−(CH2)wNR24R25 ,−(CH2)wOR23,−(CH2)wR23又はハロゲンであり; R15,R16,R23,R24及びR25は独立して水素、又は任意的にハロゲン、− N(R26)R27、ヒドロキシル、C1-6アルコキシ、C1-6アルコキシカルボニル 、C1-6アルキルカルボニルオキシもしくはアリールにより置換されたC1-6アル キルであるか、又は R16は であり、ここで Q1は−CH<又は−N<であり; T1及びJ1は独立して−CH2−,−CO−,−O−,−S−,NR28−又は原子価 結合であり; ここでR28は水素又は直鎖もしくは枝分れC1-6アルキルであり; t及びuは独立して0,1,2,3又は4であり; R17はアリールにより置換されたC1-6アルキルであり; R18はC1-6アルキルであり; R26及びR27は独立して水素又はC1-6アルキルであり; v及びwは独立して0,1,2又は3であり; R10aは水素、アリール、又はC1-6アルキルであり; 1は0,1,2又は3であり; A1は であり、ここで R29,R30,R31,R32,R33,R34,R35及びR36は独立して水素又は任意 的にハロゲン、アミノ、ヒドロキシもしくはアリールにより置換されたC1-6ア ルキルであり; R33及びR34,R33及びR35、又はR34及びR35は任意的に−(CH2)i−Z−(C H2)j−を形成してよく、ここでi及びjは独立して1又は2であり、そしてZは −O−,−S−又は原子価結合であり; n,m及びqは独立して0,1,2又は3であり; o及びpは独立して0又は1であり; Mは−CR37=CR38−,−O−,−S−又は原子価結合であり; R37及びR38は独立して水素、又は任意的にアリールで置換されたC1-6アル キルであり; A2は であり、ここで R29,R30,R31,R32,R33,R34,R35及びR36は独立して水素又は任意 的にハロゲン、アミノ、ヒドロキシルもしくはアリールにより置換されたC1-6 アルキルであり; R33及びR34,R33及びR35、又はR34及びR35は任意的に−(CH2)i−Z−(C H2)j−を形成してよく、ここでi及びjは独立して1又は2であり、そしてZは −O−,−S−又は原子価結合であり; n,m及びqは独立して0,1,2又は3であり; o及びpは独立して0又は1であり; Mは−CR37=CR38−,−O−又は−S−であり; R37及びR38は独立して水素、又は任意的にアリールで置換されたC1-6アル キルであり; G1は水素、ハロゲン、アリール、C1-6アルキル、C1-6アルコキシ、−CONR3 9 R40,−(CH2)e−NR39SO2R41,−(CH2)e−NR39COR40,−(CH2)e−OR41,−(CH2)e −OCOR40,−CH(R39)R40,−CON39−NR40R42,−(CH2)e−NR39−CS−NR40R42 ,(CH2)e−NR39−CO−NR40R42, であり、ここで X5は−N(R43)−,−O−又は−S−であり; X6は−C(R44)=又は−N=であり; X7は−C(R45)=又は−N=であり; X8は−C(R46)=又は−N=であり; R43は水素又は任意的にアリールにより置換されたC1-6アルキ ルであり; R44,R45及びR46は独立して水素、−COOR47,−CONR48R49,−(CH2)fNR48R49 ,−(CH2)fOR47,−(CH2)fR47又はハロゲンであり; R39,R40,R47,R48及びR49は独立して水素又は任意的にハロゲンで置換 されたC1-6アルキル、 −N(R50)R51、ヒドロキシル、C1-6アルコキシ、C1-6アルコキシカルボ ニル、C1-6アルキルカルボニルオキシ又はアリールであるか、又は R40は であり、ここで Q2は−CH<又は−N<であり; J2及びT2は独立して−CH2−,−CO−,−O−,−S−,−NR52−又は原子 価結合であり; ここでR52は水素又はC1-6アルキルであり; x及びyは独立して0,1,2,3又は4であり; R41はアリールで置換されたC1-6アルキルであり; R42はC1-6アルキルであり; R50及びR51は独立して水素又はC1-6アルキルであり; e及びfは独立して0,1,2又は3であり; G2は水素又はC1-6アルキルであり; R1は水素又はC1-6アルキルであり; R2は水素、−C(=O)−R54又はC1-6アルキルであり; R1及びR2は一緒になって次のタイプの架橋を形成してよく ここでR55及びR56は独立して水素、任意的にヒドロキシル、C1-6アルコキ シル又はアリールで置換されたC1-6アルキルであり R55及びR56は一緒になって=O又は=Sを形成してよく; c及びdは独立して0,1又は2であり; c+dは0,1又は2であり; R54は水素又はC1-6アルキルであり; R3及びR4は水素、任意的にヒドロキシルC1-6アルコキシル、ハロゲン又は アリールで置換されたC1-6アルキルであり; R3及びR4は一緒になって=S又は=Oを形成してよく; L1はCR57又はNであり; L2はCR58又はNであり; R57及びR58は独立して水素、任意的にヒドロキシル、ハロゲン、C1-6アル コキシル又はアリールで置換されたC1-6アルキルであり; a及びbは独立して、0,1,2又は3である; 但し、 GがG2であり、そしてL1がCR55であり、そしてL2がCR56のとき、AはA2で あり; GがG1であり、そしてL1がCR55であり、そしてL2がCR56のとき、AはA1で あり、そしてR2は−C(=O)−R54であるか、又はR1及びR2は一緒になっ て次のタイプの架橋を形成しており: L1又はL2のいづれかがNのとき、GはG1であり、そしてAはA1である) 又はその薬理学的に許容される塩。 3.Aが であり、ここでR33が水素又は任意的にヒドロキシで置換されたC1-6アルキ ルであり、 R34及びR35が独立してC1-6アルキルであり、 R36が水素であり、 Mが−CR37=CR38−又は−O−であり、ここでR37及びR38は水素又はC1-6 アルキルであり、pが1、mが1、oが0又は1、そしてnが0又は1である、 請求項1又は2記載の化合物。 4.Aが であり、 ここでMは−O−又は−S−であり、 oが0又は1であり、 qが0,1又は2であり、そして m+nが3又は4である、 請求項1又は2記載の化合物。 5.Aがであり、ここでR33が水素又はC1-6アルキルであり、 R34及びR35が独立して水素又はC1-6アルキルであり、 mが0又は1、nが0又は1、そしてpが0又は1である、 請求項1又は2記載の化合物。 6.Dが であり、ここでR5,R6,R7,R8及びR9が独立して水素又はアリールであ る、請求項1〜5のいづれか1項記載の化合物。 7.Dが であり、ここでR5及びR6が独立して水素又はC1-6アルキルである、請求項 1〜5のいづれか1項記載の化合物。 8.Eが であり、ここでR10及びR11が独立して水素又はC1-6アルキルである、請求 項1〜7のいづれか1項記載の化合物。 9.Eが であり、ここでR10,R11,R12,R13及びR14は独立して水素、−(CH2)v− NR15SO2R17,−(CH2)v−NR15COR16又は−(CH2)v−OR17であり、ここでvは0又 は1であり、R15は水素又はC1-6アルキルであり、R16は水素又は任意的に− N(R26)R27で置換されたC1-6アルキルであり、ここでR26及びR27は独立 して水素又はC1-6アルキルであり、R17はアルキル又は任意的にヒドロキシル もしくはフェニルで置換されたフェニルであるか、又はR2及びR10は一緒にな って−CH2−もしくは−CH2−CH2−を形成し ていてよい、請求項1,3〜7のいづれか1項記載の化合物。 10.Eが であり、ここでR10,R11,R12,R13及びR14は独立して水素、−(CH2)v− NR15SO2R17,−(CH2)v−NR15COR16又は−(CH2)v−OR17であり、ここでvは0又 は1であり、R15は水素又はC1-6アルキルであり、R16は水素又は任意的に− N(R26)R27で置換されたC1-6アルキルであり、ここでR26及びR27は独立 して水素又はC1-6アルキルであり、R17はフェニルで置換されたC1-6アルキル である、請求項2記載の化合物。 11.Gが水素又は−CONR39R40であり、ここでR39及びR40は独立して水素又 はC1-6アルキルである、請求項1〜10のいづれか1項記載の化合物。 12.R1が水素又はC1-6アルキルである、請求項1〜11のいづれか1項記載の 化合物。 13.R2が水素、−C(=O)−R54又はC1-6アルキルであり、ここでR54は C1-6アルキルである、請求項1〜12のいづれか1項記載の化合物。 14.R1及びR2が一緒になって次のタイプの架橋を形成している (式中、 R55及びR56は水素であるか、又は R55及びR55は一緒になって=O又は=Sを形成していてよく、 c及びdは独立して0,1又は2であり、 c+dは0,1又は2である)、請求項1〜11のいづれか1項記載の化合物。 15.R2及びR10が一緒になって−(CH2)r−を形成していてよく、ここでrは 1,2又は3である、請求項1,3〜12のいづれか1項記載の化合物。 16.R3が水素又はC1-6アルキルである、請求項1〜15のいづれか1項記載の 化合物。 17.R4が水素又はC1-6アルキルである、請求項1〜16のいづれか1項記載の 化合物。 18.R3及びR4が一緒になって=Oを形成している、請求項1〜15のいづれか 1項記載の化合物。 19.aが1である、請求項1〜18のいづれか1項記載の化合物。 20.bが0又は1である、請求項1〜19のいづれか1項記載の化合物。 21.L1が−CH−である、請求項1〜20のいづれか1項記載の化合物。 22.L2が−CH−又は>N−である、請求項1〜21のいづれか1項記載の化合 物。 23.下記の群から選ばれる、請求項1記載の化合物: 1−((2R)−2−(N−((2E)−5−アミノ−5−メチルヘキス−2 −エノイル)−N−メチルアミノ)−3−(2−ナフチル)プロピオニル)−2 −ベンジル−4−エチルセミカルバジド、 1−((2R)−2−(N−(2−(((2S)−ピロリジン− イル)メトキシ)アセチル)−N−メチルアミノ)−3−(2−ナフチル)プロ ピオニル)−2−ベンジル−4−エチルセミカルバジド、 1−((2R)−2−(N−((2−アミノ−2−メチルプロポキシ)アセチ ル)−N−メチルアミノ)−3−(2−ナフチル)プロピオニル)−2−ベンジ ル−4−エチルセミカルバジド、 (2R)−2−((5R)−4−((2E)−5−アミノ−5−メチルヘキス −2−エノイル)−5−(2−ナフチル)メチル−2−オキソピペラジン−1− イル)−N−メチル−3−フェニルプロピオナミド、 (2R)−2−(N−((2E)−5−アミノ−5−メチルヘキス−2−エノ イル)−N−メチルアミノ)−3−(2−ナフチル)プロピオン酸N−メチル− N−フェネチルアミド、又はそのトリフルオロ酢酸塩、 (2R)−2−(N−((2E)−5−アミノ−5−メチルヘキス−2−エノ イル)−N−メチルアミノ)−3−(2−ナフチル)プロピオン酸N−メチル− N−(2−(2−メチルスルホニルアミノ)フェニル)エチル)アミド、 (2R)−2−(N−((2E)−5−アミノ−5−メチルヘキス−2−エノ イル)−N−メチルアミノ)−3−(2−ナフチル)プロピオン酸N−メチル− N−(2−(2−チエニル)エチル)アミド、 (2R)−2−(N−((2E)−5−((2R)−2−ヒドロキシプロピル アミノ)−5−メチルヘキス−2−エノイル)−N−メチルアミノ)−N−メチ ル−3−(2−ナフチル)−N−フェネチルプロピオナミド又はそのトリフルオ ロ酢酸塩、 (3R)−4−((2E)−5−アミノ−5−メチルヘキス−2 −エノイル)−3−((2−ナフチル)メチル)−1−フェネチルピペラジン− 2−オン、 (2E)−5−アミノ−5−メチルヘキス−2−エノン酸N−((1R)−2 −(N−アセチル−N−((1R)−1−(メチルカルバモイル)−2−フェニ ルエチル)アミノ)−1−((2−ナフチル)メチル)エチル)アミド、 (2E)−5−アミノ−5−メチル−N−メチル−N−((1R)−1−(N −メチル−N−(2−(2−チエニル)エチル)カルバモイル)−2−(2−ナ フチル)エチル)ヘキス−2−エナミド、 (2E)−5−メチル−5−(メチルアミノ)−N−メチル−N−((1R) −1−(N−メチル−N−(2−(2−チエニル)エチル)カルバモイル)−2 −(2−ナフチル)エチル)ヘキス−2−エナミド、 (2E)−5−アミノ−5−メチルヘキス−2−エノン酸N−メチル−N−( (1R)−1−(N−メチル−N−(3−フェニルプロピル)カルバモイル)− 2−(2−ナフチル)エチル)アミド、 (2R)−2−(N−(3−(1−アミノエチル)ベンゾイル)−N−メチル アミノ)−N−メチル−3−(2−ナフチル)−N−(2−(2−チエニル)エ チル)プロピオナミド、 (2E)−5−アミノ−5−メチルヘキス−2−エノン酸N−((1R)−2 −(1,2,3,4−テトラヒドロイソキノリン−2−イル)−1−((2−ナ フチル)メチル)−2−オキソエチル)−N−メチルアミド、 (2E)−5−メチル−N−メチル−5−(メチルアミノ)−N−((1R) −1−(N−メチル−N−フェネチルカルバモイル)−2−(2−ナフチル)エ チル)ヘキス−2−エナミド、 (2R)−2−(N−((2E)−5−アミノ−5−メチルヘキス−2−エノ イル)−N−メチルアミノ)−N−(2−(2−(2−ヒドロキシエトキシ)フ ェニル)エチル)−N−メチル−3−(2−ナフチル)プロピオナミド、 (2R)−2−(N−((2E)−5−アミノ−5−メチルヘキス−2−エノ イル)−N−メチルアミノ)−N−メチル−3−(2−ナフチル)−N−(2− (2−メチルスルホニルアミノフェニル)エチル)プロピオナミド、 (2E)−5−アミノ−N−((1R)−2−(ビフェニル−4−イル)−1 −(N−メチル−N−(2−(2−チエニル)エチル)カルバモイル)エチル) −5−メチル−N−メチルヘキス−2−エナミド、 (2E)−N−((1R)−1−(N−(2−(2−(2−ヒドロキシエトキ シ)フェニル)エチル)−N−メチルカルバモイル)−2−(2−ナフチル)エ チル)−N−メチル−5−メチル−5−(メチルアミノ)ヘキス−2−エナミド 、 3−アミノメチル−N−〔(1R)−1−(N−{2−〔2−(2−ヒドロキ シエトキシ)フェニル〕エチル}−N−メチルカルバモイル)−2−(2−ナフ チル)エチル〕ベンズアミド、 (2E)−5−アミノ−5−メチルヘキス−2−エノン酸N−((1R)−1 −(N−(2−(2−(2−ヒドロキシエトキシ)フェニル)エチル)−N−メ チルカルバモイル)−2−(2−ナフチル)エチル)−N−メチルアミド、 (2E)−5−アミノ−5−メチルヘキス−2−エノン酸N−((1R)−1 −{N−〔2−(2−ベンゼンスルホニルアミノ)フェニル)エチル〕−N−メ チルカルバモイル}−2−(2−ナフチル)エチル)−N−メチルアミド、 2−アミノ−N−(2−(2−(N−((2R)−2−(N−(2E)−5− アミノ−5−メチルヘキス−2−エノイル)−N−メチルアミノ)−3−(2− ナフチル)プロピオニル)−N−メチルアミノ)エチル)フェニル)アセトアミ ド、 (2R)−2−(N−((2E)−5−アミノ−5−メチルヘキス−2−エノ イル)−N−メチルアミノ)−N−(2−(2−(3−ヒドロキシプロポキシ) フェニル)エチル)−N−メチル−3−(2−ナフチル)プロピオナミド、 3−アミノメチル−N−〔(1R)−(N−{2−〔2−(2−ヒドロキシエ トキシ)フェニル〕エチル}−N−メチルカルバモイル)−2−(2−ナフチル )エチル〕ベンズアミド、 (2E)−5−アミノ−5−メチルヘキス−2−エノン酸N−((1R)−1 −(N−(2−(2−(2−ヒドロキシエトキシ)フェニル)エチル)−N−メ チルカルバモイル)−2−(2−ナフチル)エチル)アミド、及び (3R)−4−((2E)−5−アミノ−5−メチルヘキス−2−エノイル) −3−((2−ナフチル)メチル)−1−フェネチルピペラジン−2−オン又は その薬理学的に許容される塩、例えば酢酸塩。 24.薬理組成物であって、活性成分として、請求項1〜23のいづれか1項記載 の化合物又はその薬理学的に許容される塩を、薬理学的に許容される担体又は希 釈と一緒に含んで成る、薬理組成物。 25.約10〜約200mgの請求項1〜23のいづれか1項記載の化合物又はその薬理 学的に許容される塩を含んで成る、単位投与形態の請求項24記載の組成物。 26.下垂体からの成長ホルモンの放出を刺激するための薬理組成物であって、 活性成分として、請求項1〜23のいづれか1項記載の 化合物又はその薬理学的に許容される塩を薬理学的に許容される担体又は希釈と 一緒に含んで成る、薬理組成物。 27.動物の成長の速度及び度合いを増加させるため、その乳生産及び体毛生産 を増加させるため、又はその疾患の処置のために動物に投与する薬理組成物であ って、請求項1〜23のいづれか1項記載の化合物又はその薬理学的に許容される 塩を薬理学的に許容される担体又は希釈と一緒に含んで成る、薬理組成物。 28.経口、鼻、経皮、肺又は非経腸投与のための請求項24〜27のいづれか1項 に記載の薬理組成物。 29.下垂体からの成長ホルモンの放出を刺激する方法であって、それを必要と する被検体に請求項1〜23のいづれか1項記載の化合物又はその薬理学的に許容 される塩又は請求項24〜26もしくは28のいづれか1記載の組成物を投与すること を含んで成る方法。 30.前記請求項1〜23のいづれか1項記載の化合物又はその薬理学的に許容さ れる塩もしくはそのエステルの有効量が1日当り約0.0001〜約100mg/kg体重、 好ましくは1日当り約0.001〜約50mg/kg体重である、請求項29記載の方法。 31.動物の成長の速度及び度合いを増加させるため、動物の乳生産もしくは体 毛生産を増加させるため、又は疾患の処置のための方法であって、それを必要と する動物に有効量の請求項1〜23のいづれか1項記載の化合物又はその薬理学的 に許容される塩又は請求項24,25,27もしくは28のいづれか1項に記載の組成物 を投与することを含んで成る方法。 32.前記投与が経口、鼻、経皮、肺又は非経腸ルートにより行われる、請求項 29〜31のいづれか1項記載の方法。 33.医薬の調製のための、請求項1〜23のいづれか1項記載の化合物又はその 薬理学的に許容される塩の利用。 34.下垂体からの成長ホルモンの放出を刺激するための、請求項1〜23のいづ れか1項記載の化合物又はその薬理学的に許容される塩の利用。 35.動物の成長の速度及び度合いを増加させるため、動物の乳生産もしくは体 毛生産を増加させるため、又は疾患の処置のための医薬の調製のための請求項1 〜23のいづれか1項記載の化合物又はその薬理学的に許容される塩の利用。 36.高齢者における成長ホルモン放出の刺激処置;糖質コルチコイドの異化副 作用の予防、オステオポローシスの予防の治療、免疫系の刺激、創傷治癒の促進 、骨折修復の促進、成長遅滞の治療、成長遅滞に起因する腎不全もしくは機能不 全の治療、成長ホルモン欠損児童を含む生理学的不足状態及び慢性疾患に関連し た不足状態の治療、肥満及び肥満に関連した成長遅滞の治療、食欲不振の処置、 NIDDMの処置、Prader−Willi症候群及びTurner症候群に関連した成長遅滞の治療 ;火傷患者の回復の促進及び入院の削減;子宮内発育遅滞、骨格形成異常、高コ ルチコイド症及びCushing症候群の治療;拍動性成長ホルモン放出の誘導;スト レス患者における成長ホルモンの代用、骨軟骨形成異常、Noonan症候群、精神分 裂病、うつ病、アルツハイマー病、遅延損傷治癒及び心理社会的剥奪の治療、肺 機能不全及び呼吸器依存症の治療、大手術後のタンパク質異化反応の減衰、癌や エイズ(AIDS)のような慢性疾患によるタンパク損失及び悪液質の減少;膵島細 胞症を含む高インスリン血症の治療、排卵誘発のためのアジュバント療法;胸腺 の発育を刺激するため及び加齢に伴う胸腺機能の衰退を防ぐため、免疫抑制患者 の治療、筋肉強度、運動性の向上、高齢者における皮膚の厚さ、代謝恒常性、腎 恒常性の維持、骨芽細胞、骨再造形及び軟骨成長の刺激、伴生動物における免疫 系の刺激、伴生動物における高齢疾患の治療、家畜 の成長促進並びにヒツジにおける増毛の刺激に用いる薬剤の調製のための、請求 項1〜23のいづれか1項記載の化合物又はその薬理学的に許容される塩の利用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK0803/96 | 1996-07-22 | ||
| DK80396 | 1996-07-22 | ||
| PCT/DK1997/000314 WO1998003473A1 (en) | 1996-07-22 | 1997-07-17 | Compounds with growth hormone releasing properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000515517A true JP2000515517A (ja) | 2000-11-21 |
| JP2000515517A5 JP2000515517A5 (ja) | 2005-03-10 |
| JP4425992B2 JP4425992B2 (ja) | 2010-03-03 |
Family
ID=8097747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50646598A Expired - Lifetime JP4425992B2 (ja) | 1996-07-22 | 1997-07-17 | 成長ホルモン放出特性を有する化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US5922770A (ja) |
| EP (2) | EP1184370B1 (ja) |
| JP (1) | JP4425992B2 (ja) |
| AT (2) | ATE218537T1 (ja) |
| AU (1) | AU3434697A (ja) |
| DE (2) | DE69734215T2 (ja) |
| WO (1) | WO1998003473A1 (ja) |
| ZA (1) | ZA976371B (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008505078A (ja) * | 2004-06-29 | 2008-02-21 | サファイア セラピューティクス インコーポレイテッド | (3r)−1−(2−メチルアラニル−d−トリプトフィル)−3−(フェニルメチル)−3−ピペリジンカルボン酸1,2,2−トリメチルヒドラジドの結晶形 |
| JP2008509930A (ja) * | 2004-08-12 | 2008-04-03 | サファイア セラピューティクス インコーポレイテッド | 成長ホルモン分泌促進物質を利用して胃腸系の運動性を刺激する方法 |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998058950A1 (en) * | 1997-06-20 | 1998-12-30 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6127341A (en) * | 1997-06-20 | 2000-10-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| CZ301276B6 (cs) * | 1998-05-11 | 2009-12-30 | Novo Nordisk A/S | Piperidinový derivát vykazující schopnost uvolnování rustového hormonu |
| TW450954B (en) * | 1998-05-14 | 2001-08-21 | Pharmacia & Amp Upjohn Company | Phenylsulfonamide-phenylethylamines useful as dopamine receptors |
| US6919315B1 (en) | 1998-06-30 | 2005-07-19 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| CN1304424C (zh) * | 1998-06-30 | 2007-03-14 | 诺沃挪第克公司 | 具有生长激素释放特性的化合物 |
| US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| KR100699404B1 (ko) | 1999-02-18 | 2007-03-23 | 가켄 세야쿠 가부시키가이샤 | 성장 호르몬 분비촉진제로서의 신규 아미드 유도체 |
| UA73530C2 (uk) * | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
| AU2001252958A1 (en) * | 2000-03-23 | 2001-10-03 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
| ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| CA2410680A1 (en) * | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
| US6667336B2 (en) * | 2001-02-16 | 2003-12-23 | Nps Allelix Corp. | GlyT-1 inhibitors |
| CA2440042C (en) * | 2001-03-05 | 2011-09-27 | Transtech Pharma, Inc. | Carboxamide derivatives as therapeutic agents |
| CN1235583C (zh) * | 2001-03-05 | 2006-01-11 | 特兰斯泰克制药公司 | 用作治疗剂的苯并咪唑衍生物 |
| CA2452039A1 (en) * | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| US20070213407A1 (en) * | 2001-06-29 | 2007-09-13 | Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc | Compounds to treat Alzheimer's disease |
| MXPA04006709A (es) * | 2002-01-11 | 2004-10-04 | Sankyo Co | Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen. |
| US7230133B2 (en) | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
| CN1805743A (zh) * | 2003-05-20 | 2006-07-19 | 特兰斯泰克制药公司 | 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂 |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| KR20110136901A (ko) | 2004-02-24 | 2011-12-21 | 상꾜 가부시키가이샤 | 아미노 알코올 화합물 |
| US20050261201A1 (en) * | 2004-03-30 | 2005-11-24 | Rejuvenon Corporation | Method of reducing C-reactive protein using growth hormone secretagogues |
| WO2007023948A1 (ja) | 2005-08-25 | 2007-03-01 | Ube Industries, Ltd. | 光学活性(S又はR)-α-アミノ酸及び光学活性(R又はS)-α-アミノ酸エステルの製造方法 |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| ES2602789T3 (es) | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina |
| KR20090112720A (ko) * | 2007-02-13 | 2009-10-28 | 헬신 세라퓨틱스 (유.에스.) 인크. | 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법 |
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| UA105657C2 (uk) | 2009-02-27 | 2014-06-10 | Хелсінн Терапьютікс (Ю.Ес.), Інк. | Поліпшені способи лікування мігрені на основі анамореліну |
| CA2772797C (en) | 2009-09-30 | 2018-09-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| KR20150064743A (ko) | 2012-10-05 | 2015-06-11 | 트랜스테크 파르마 엘엘씨 | 경도 및 중등도 알츠하이머 병의 치료 |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| WO2017139317A1 (en) | 2016-02-09 | 2017-08-17 | Lumeova, Inc | Ultra-wideband, wireless optical high speed communication devices and systems |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| JP7464591B2 (ja) | 2018-10-10 | 2024-04-09 | ブイティーブイ・セラピューティクス・エルエルシー | [3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2179597A1 (en) * | 1993-12-23 | 1995-06-29 | Nils Langeland Johansen | Compounds with growth hormone releasing properties |
| MY113488A (en) * | 1995-01-27 | 2002-03-30 | Novo Nordisk As | Compounds with growth hormone releasing properties |
| AU715856B2 (en) * | 1995-12-22 | 2000-02-10 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
-
1997
- 1997-07-17 EP EP01123155A patent/EP1184370B1/en not_active Expired - Lifetime
- 1997-07-17 AU AU34346/97A patent/AU3434697A/en not_active Abandoned
- 1997-07-17 DE DE69734215T patent/DE69734215T2/de not_active Expired - Lifetime
- 1997-07-17 AT AT97930368T patent/ATE218537T1/de not_active IP Right Cessation
- 1997-07-17 WO PCT/DK1997/000314 patent/WO1998003473A1/en not_active Ceased
- 1997-07-17 DE DE69713109T patent/DE69713109T2/de not_active Expired - Lifetime
- 1997-07-17 AT AT01123155T patent/ATE304528T1/de not_active IP Right Cessation
- 1997-07-17 EP EP97930368A patent/EP0923539B1/en not_active Expired - Lifetime
- 1997-07-17 JP JP50646598A patent/JP4425992B2/ja not_active Expired - Lifetime
- 1997-07-17 US US08/896,550 patent/US5922770A/en not_active Expired - Lifetime
- 1997-07-18 ZA ZA9706371A patent/ZA976371B/xx unknown
-
1999
- 1999-03-17 US US09/270,862 patent/US6127354A/en not_active Expired - Lifetime
-
2000
- 2000-07-19 US US09/619,227 patent/US6274584B1/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008505078A (ja) * | 2004-06-29 | 2008-02-21 | サファイア セラピューティクス インコーポレイテッド | (3r)−1−(2−メチルアラニル−d−トリプトフィル)−3−(フェニルメチル)−3−ピペリジンカルボン酸1,2,2−トリメチルヒドラジドの結晶形 |
| JP2008509930A (ja) * | 2004-08-12 | 2008-04-03 | サファイア セラピューティクス インコーポレイテッド | 成長ホルモン分泌促進物質を利用して胃腸系の運動性を刺激する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA976371B (en) | 1998-01-22 |
| ATE304528T1 (de) | 2005-09-15 |
| DE69713109D1 (de) | 2002-07-11 |
| DE69734215D1 (de) | 2005-10-20 |
| US6127354A (en) | 2000-10-03 |
| EP0923539B1 (en) | 2002-06-05 |
| EP1184370B1 (en) | 2005-09-14 |
| DE69713109T2 (de) | 2003-01-02 |
| US6274584B1 (en) | 2001-08-14 |
| ATE218537T1 (de) | 2002-06-15 |
| EP1184370A3 (en) | 2002-03-27 |
| JP4425992B2 (ja) | 2010-03-03 |
| AU3434697A (en) | 1998-02-10 |
| WO1998003473A1 (en) | 1998-01-29 |
| EP0923539A1 (en) | 1999-06-23 |
| DE69734215T2 (de) | 2006-06-29 |
| EP1184370A2 (en) | 2002-03-06 |
| US5922770A (en) | 1999-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4425992B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| JP3701686B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| JP4073952B2 (ja) | 成長ホルモン放出特性をもつ化合物 | |
| JP4938708B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| JP4359859B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| JP4116097B2 (ja) | 成長ホルモン放出特性をもつ化合物 | |
| JP4382279B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| JP2002519436A (ja) | 成長ホルモン放出特性を有する化合物 | |
| JP4481502B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| JP2002535240A (ja) | トリペプチジルペプチダーゼインヒビター | |
| JP3007613B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| MXPA00006692A (en) | Compounds with growthhormone releasing properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040708 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040708 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080729 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080716 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081028 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090128 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090512 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090910 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091029 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091110 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091210 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131218 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |